Home Cart Sign in  
Chemical Structure| 635318-11-5 Chemical Structure| 635318-11-5

Structure of LY404039
CAS No.: 635318-11-5

Chemical Structure| 635318-11-5

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

LY404039 is an inhibitor for mGluR1 (Ki=149 nM) and mGluR2 (Ki= 92 nM), which can also inhibit dopamine receptor.

Synonyms: pomaglumetad

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of LY404039

CAS No. :635318-11-5
Formula : C7H9NO6S
M.W : 235.21
SMILES Code : O=C([C@]1(N)CS([C@@]2([H])[C@H](C(O)=O)[C@@]12[H])(=O)=O)O
Synonyms :
pomaglumetad
MDL No. :MFCD11974011
InChI Key :AVDUGNCTZRCAHH-MDASVERJSA-N
Pubchem ID :9834591

Safety of LY404039

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P280-P301+P312-P302+P352-P305+P351+P338

Related Pathways of LY404039

GPCR

Isoform Comparison

Biological Activity

Description
LY404039 is a potent and selective mGluR2 and mGluR3 agonist with dissociation constants (Kis) of 149 nM for mGluR2 and 92 nM for mGluR3 in recombinant human receptors, exhibiting over 100-fold selectivity for these receptors over other receptors and transporters. LY404039 has demonstrated both antipsychotic and anxiolytic effects[1].

In Vitro:

Cell Line
Concentration Treated Time Description References
HeLa cells 30 µM 1, 2.5, 5, 7.5, 10, 15 minutes To determine if LY2140023 or LY404039 were substrates of PEPT1. The results showed that LY404039 was not a substrate of PEPT1, while LY2140023 was a substrate of PEPT1. PMC5267515

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Rats Sub-chronic ketamine exposure model Subcutaneous injection 10 mg/kg Once daily for 14 days To evaluate the effectiveness of LY404039 in restoring ketamine-induced cognitive deficits. Results showed that LY404039 failed to reverse ketamine-induced deficits and impaired performance in control animals at the highest dose. PMC3230506
Mice C57BL/6 mice Intraperitoneal injection 6.25, 12.5, 20, 25, 35 mg/kg Once daily or intermittent dosing (3 days on, 2 days off) To assess the modulatory effect of LY404039 on DOI-induced head-twitch response (HTR). Results showed that LY404039 induced a dose-dependent attenuation of DOI-induced HTR response at early time points (<45 min), but a dose-dependent potentiation of HTR occurred at later time points (>45 min). PMC6776537

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT01609218 Healthy Volunteer Study Phase 1 Completed - United Kingdom ... More >> For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Leeds, West Yorkshire, United Kingdom, LS2 9LH Less <<
NCT01475136 Hepatic Insufficiency Phase 1 Completed - Germany ... More >> For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Munich, Germany, 81241 Hungary For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Balatonfüred, Hungary, 8230 Less <<
NCT01659177 Healthy Participants Phase 1 Withdrawn(The decision to stop... More >> the trial was based on efficacy results in the overall schizophrenia patient population.) Less << September 2012 Switzerland ... More >> For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Allschwil, Switzerland, CH-4123 Less <<
NCT01637142 Healthy Participants Phase 1 Completed - United Kingdom ... More >> For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Leeds, West Yorkshire, United Kingdom, LS2 9LH Less <<
NCT01440478 Healthy Subjects Phase 1 Completed - United Kingdom ... More >> For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559), Mon - Fri, from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician. Leeds, United Kingdom Less <<
NCT01591330 Healthy Volunteers Phase 1 Completed - United Kingdom ... More >> For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Leeds, West Yorkshire, United Kingdom Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

4.25mL

0.85mL

0.43mL

21.26mL

4.25mL

2.13mL

42.52mL

8.50mL

4.25mL

Dissolving Methods
The prepared working fluid is recommended to be prepared now and used up as soon as possible in a short period of time. The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1

References

 

Historical Records

Categories